These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33400301)

  • 1. CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
    Wang HT; Zhu ZA; Li YY; Lou SS; Yang G; Feng X; Xu W; Huang ZL; Cheng X; Xiong ZQ
    Epilepsia; 2021 Feb; 62(2):517-528. PubMed ID: 33400301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
    Mulcahey PJ; Tang S; Takano H; White A; Davila Portillo DR; Kane OM; Marsh ED; Zhou Z; Coulter DA
    Exp Neurol; 2020 Oct; 332():113388. PubMed ID: 32585155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKL5 deficiency in adult glutamatergic neurons alters synaptic activity and causes spontaneous seizures via TrkB signaling.
    Zhu ZA; Li YY; Xu J; Xue H; Feng X; Zhu YC; Xiong ZQ
    Cell Rep; 2023 Oct; 42(10):113202. PubMed ID: 37777961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
    Terzic B; Cui Y; Edmondson AC; Tang S; Sarmiento N; Zaitseva D; Marsh ED; Coulter DA; Zhou Z
    Neurobiol Dis; 2021 Jan; 148():105176. PubMed ID: 33197557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A GABA
    Gennaccaro L; Fuchs C; Loi M; Roncacè V; Trazzi S; Ait-Bali Y; Galvani G; Berardi AC; Medici G; Tassinari M; Ren E; Rimondini R; Giustetto M; Aicardi G; Ciani E
    Neurobiol Dis; 2021 Jun; 153():105304. PubMed ID: 33621640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKL5 Deficiency Augments Inhibitory Input into the Dentate Gyrus That Can Be Reversed by Deep Brain Stimulation.
    Hao S; Wang Q; Tang B; Wu Z; Yang T; Tang J
    J Neurosci; 2021 Oct; 41(43):9031-9046. PubMed ID: 34544833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
    Tang S; Terzic B; Wang IJ; Sarmiento N; Sizov K; Cui Y; Takano H; Marsh ED; Zhou Z; Coulter DA
    Nat Commun; 2019 Jun; 10(1):2655. PubMed ID: 31201320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
    Yennawar M; White RS; Jensen FE
    J Neurosci; 2019 Jun; 39(24):4814-4828. PubMed ID: 30952813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced hippocampal LTP but normal NMDA receptor and AMPA receptor function in a rat model of CDKL5 deficiency disorder.
    Simões de Oliveira L; O'Leary HE; Nawaz S; Loureiro R; Davenport EC; Baxter P; Louros SR; Dando O; Perkins E; Peltier J; Trost M; Osterweil EK; Hardingham GE; Cousin MA; Chattarji S; Booker SA; Benke TA; Wyllie DJA; Kind PC
    Mol Autism; 2024 Jun; 15(1):28. PubMed ID: 38877552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
    Galvani G; Mottolese N; Gennaccaro L; Loi M; Medici G; Tassinari M; Fuchs C; Ciani E; Trazzi S
    J Neuroinflammation; 2021 Jul; 18(1):155. PubMed ID: 34238328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKL5-mediated developmental tuning of neuronal excitability and concomitant regulation of transcriptome.
    Liao W; Lee KZ
    Hum Mol Genet; 2023 Nov; 32(23):3276-3298. PubMed ID: 37688574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mGluR5 PAMs rescue cortical and behavioural defects in a mouse model of CDKL5 deficiency disorder.
    Gurgone A; Pizzo R; Raspanti A; Chiantia G; Devi S; Comai D; Morello N; Pilotto F; Gnavi S; Lupori L; Mazziotti R; Sagona G; Putignano E; Nocentini A; Supuran CT; Marcantoni A; Pizzorusso T; Giustetto M
    Neuropsychopharmacology; 2023 May; 48(6):877-886. PubMed ID: 35945276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder.
    Van Bergen NJ; Massey S; Stait T; Ellery M; Reljić B; Formosa LE; Quigley A; Dottori M; Thorburn D; Stroud DA; Christodoulou J
    Neurobiol Dis; 2021 Jul; 155():105370. PubMed ID: 33905871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early-onset brain alterations during postnatal development in a mouse model of CDKL5 deficiency disorder.
    Tassinari M; Uguagliati B; Trazzi S; Cerchier CB; Cavina OV; Mottolese N; Loi M; Candini G; Medici G; Ciani E
    Neurobiol Dis; 2023 Jun; 182():106146. PubMed ID: 37164289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.
    Katayama S; Sueyoshi N; Inazu T; Kameshita I
    Neural Plast; 2020; 2020():6970190. PubMed ID: 32587608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the phenotype of the CDKL5 deficiency disorder: Are seizures mandatory?
    MacKay CI; Bick D; Prokop JW; Muñoz I; Rouse J; Downs J; Leonard H
    Am J Med Genet A; 2020 May; 182(5):1217-1222. PubMed ID: 32034940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
    Loi M; Trazzi S; Fuchs C; Galvani G; Medici G; Gennaccaro L; Tassinari M; Ciani E
    Mol Neurobiol; 2020 May; 57(5):2244-2262. PubMed ID: 32002787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
    Fuchs C; Medici G; Trazzi S; Gennaccaro L; Galvani G; Berteotti C; Ren E; Loi M; Ciani E
    Brain Pathol; 2019 Sep; 29(5):658-674. PubMed ID: 30793413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
    Fuchs C; Gennaccaro L; Ren E; Galvani G; Trazzi S; Medici G; Loi M; Conway E; Devinsky O; Rimondini R; Ciani E
    Neuropharmacology; 2020 May; 167():107746. PubMed ID: 31469994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
    Jhang CL; Lee HY; Chen JC; Liao W
    Hum Mol Genet; 2020 Aug; 29(14):2408-2419. PubMed ID: 32588892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.